anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Smoking is the largest preventable cause of disease and premature death in the United States. Adolescent smoking is the greatest predictor of adult smoking and is associated with adverse health effects during adolescence. Twenty-two percent of high school students report current smoking (past 30 days). As the primary health professional in the school setting, school nurses have a tremendous opportunity to play a key role in treating adolescent smokers. A randomized controlled trial (RCT) conducted by the investigators in 71 high schools in Massachusetts demonstrated the feasibility of school nurses delivering a four-session individual counseling intervention to adolescents who want to stop smoking and its potential efficacy in increasing self-reported short term (6-week and 3-month) quit rates. Although promising, the preliminary study lacked biochemical validation and long-term follow-up on the maintenance of the intervention effects, and was conducted with a primarily white student population. This application seeks to evaluate the effectiveness of the intervention using a more rigorous methodology, including biochemical validation of self-reported smoking behavior and longer-term follow-up (6 and 12 months post-intervention), a study design that compares the intervention to an information only attention-control condition, and recruitment from ethnically diverse schools to increase the generalizability of our findings.

The overall aim of the proposed study is to conduct a randomized controlled school-based trial (RCT) to evaluate the effectiveness of a school nurse-delivered smoking cessation intervention in increasing 30 day abstinence rates among high school students who smoke. Forty high schools serving a diverse student population will be recruited and randomly assigned to one of two conditions: (1) Special Intervention (SI) - four 30-minute individual patient-centered smoking cessation counseling intervention sessions based on the Public Health Service (PHS) clinical practice guideline delivered by school nurses; or (2) Information Only (IO) attention-control comparison condition - four individual sessions with the school nurse to check smoking status and deliver a standardized series of informational pamphlets on smoking and cessation. Participant assessments will occur at study entry (baseline) and at 3-,12-month follow-up. Thirty students enrolled in grades 9 through 12 who report smoking within the past 30 days and willingness to participate in a smoking cessation intervention study will be recruited from each school (n=1200) to provide 25 completed assessments per school at 12-month follow-up (n=1000). If found effective, the study products (i.e., intervention protocol, student materials, training manual, and estimated costs of intervention implementation) will facilitate dissemination of the intervention to school nurses nationally.
Upper limb dysfunction is a common and disabling consequence of children with cerebral palsy (CP). As children with hemiplegia primarily have one better funcitoning side of their body and one more affected side, they often tend not to use the affected extremity resulting in the phenoema of developmental disregard. Recent evidence suggests that constraint-induced therapy (CIT) is the most effective technique to improve the use of the affected hand and reduce the developmental disregard in children with CP. However, despite the cumulative evidence supporting the effects of pediatric CIT, the concerns of feasibility and gaps of current knowledge prompt us to conduct this current proposal. The concerns of the feasibility include this approach is emotionally problematic at early stages and researchers suggested that the orginal CIT protocols may be too intrusive for children and their families. The gaps of current knowledge include: no study has directly investigated the effectiveness differences between various CIT models; no study examines, monitors and compares the psychosocial outcomes while receiving the CIT protocols for children and their parents systematically and comprehensively; and no study investigates the possible clinical characteristics of children that may influence the training effects of the various CIT models.

Investigators will recruit a total of 60 children with CP from the CP Association, medical centers, and special educational systems and participants will be assigned to the two intervention groups. The intensive CIT is delivered by the group-based design with 6 hours a day for 6 days (36 hours in total) and the distributed CIT will be delivered by individualized home-based intervention with 2.25 hours a day, two times a week, for 8 weeks (36 hours in total).
MSEL arm consists of three intervention components: 1) CSEL, 2) the Class Ambassador (meaningful role-taking), and 3) Secret Angel . Participants in this arm will receive the same 6-session SEL training as participants in the CSEL arm. Other than CSEL, the second component is the Class Ambassador, adapted from the pupil responsibilities intervention developed by Ellies et al. (2016). The main goal of Class Ambassador is to offer autonomous, prosocial ways of acquiring recognition and social status through a variety of daily classroom jobs. The objective of Class Ambassador is to provide opportunities for students to 1) practice their social-emotional skills, 2) establish healthy peer relationships, 3) autonomously performing prosocial roles and fulfilling social responsibilities. The third component is the Secret Angel. Students will be observe, record, recognize each other's performance anonymously through appraisal notes.
The invention discloses a multi-place development design and storage method, which comprises the following steps: filling basic information and chief complaint information in a patient, registering and generating a unique visit number; the doctor inquires the symptom information of the patient, diagnoses the disease symptoms and records the corresponding information; adding information of the prescription 1 by the doctor, generating a unique prescription number, and associating the treatment number; the doctor adds the prescription 1 medication information and associates the prescription 1 number; adding new prescription 2 information by a doctor, generating a unique prescription number, and associating the treatment number; the doctor adds the prescription 2 medication information and associates the prescription 2 number; if prescription information is not added, adding can be continued; if not, ending the addition; a single or multiple prescription slips are printed as needed. The invention comprises the following steps: 1. one visit supports the prescription of multiple prescriptions. 2. Each module has definite functions, and only the key points of the module are concerned. 3. And flexibly printing single or multiple prescriptions according to needs.
The potential association between red blood cell distribution width (RDW) at admission and prognosis in patients with sepsis-induced cardiomyopathy(SIC) remains uncertain. The purpose of this study was to explore the prognostic value of RDW on mortality in patients with SIC. Data for this retrospective study were obtained from the MIMIC IV2.2 database. We used propensity score matching (PSM) and Cox proportional hazards regression analysis to evaluate the main risk factors associated with mortality in SIC patients. This analysis was utilized to develop a predictive nomogram. To assess the predictive accuracy and clinical usefulness of the model, we employed the concordance index (C-index) and decision curve analysis. To define the high- and low-RDW groups among patients with SIC, we determined the optimal cut-off value by maximizing the Youden index. According to the screening criteria, we identified a cohort of 1051 patients diagnosed with SIC. When comparing the high-RDW group to the low-RDW group, it was found that the high-RDW group exhibited longer Los_ICU(4.5 days vs.3.8 days, respectively, P = 0.009) and higher mortality rates at 28 days (33.8% vs. 7.8%, respectively, P < 0.001). A nomogram model was created using matched patients which included various factors such as Age, RDW, LDH, CKMB, creatinine and the administration of β-blocker. The C-index predicting 28-day survival probability was 0.846. Decision curves analysis demonstrated that the inclusion of RDW in the model provided a greater net benefit compared to excluding RDW. The prognosis of patients with SIC can be predicted by the RDW value. The nomogram model provides a useful tool in identifying and managing SIC patients.
FIELD: insect repellents. SUBSTANCE: invention describes N-monosubstituted neoalkaneamides with 11-14 carbon atoms where substituent at amide nitrogen is cyclic (aromatic or cycloaliphatic, in part, aryl or cycloalkyl) and involves at least 5 carbon atoms at condition that any aromatic substituent is nonsubstituted at ortho-position and pivaloyl is neoalkanoyl moiety. Total number of carbon atoms in N-cyclic neoalkaneamide is at least 12. The proposed compounds are repellents with respect to cockroaches, mosquitos, flies, ants and mites. Compounds were used in the form of solutions and emulsion or as detergents and other forms. EFFECT: prolonged repellent effect. 10 cl
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.
Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
Despite the advances in technology and ventilatory modes, mortality of ARDS is still around 40%. Besides prone positioning, the best approach of management is low tidal volume ventilation (LTV). This 'protective ventilation' strategy is not aways effective to improve oxygenation and is associated with an increased requirement of sedation and neuromuscular blocking agents, which increase length of stay and morbidity. APRV is a ventilatory mode based on relatively high and sustained continuous positive pressure, combined with a short phase of release to allow carbon dioxide removal. It also allows unrestricted spontaneous breathing throughout respiration, independent of the ventilator cycle. Providing sustained inflation while limiting duration and frequency of release phase permits limiting volume loss, resulting in progressive and improved alveolar recruitment, an increased alveolar surface area available for gas exchange and improved ventilation-perfusion matching.

In this multi-center, prospective, randomized, controlled, open trial, the investigators aim to compare the effects and safety of the early application of time-controlled adaptive method of APRV and conventional ventilation with LTV strategy in patients with severe to moderate ARDS.
Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
In the care of hydro-soft lenses, the medium in which the lenses are kept is free from substances foreign to the eyes, and has been hypertonised with 20% of salts identical to those of tears. Pref. a less strongly hypertonised surfactant cleaner, free from thickener and phosphate and contg. the usual chlorhexidine-thiomersal preservative, may be incorporated. The lens is pref. rubbed and rinsed with the soln., opt. with lather rinsing with an isotonic, isohydric salt soln., free from substances foreign to the eye. Opt., the soln. is not thrown away but is used for pre-rinsing after the surface cleaning. The case is cleaned free from grease and the hydrolens and the case are boiled for 10 mins. After boiling and cooling, the isotonic soln. free from substances foreign to the eye is exchanged and held for 10 mins. ADVANTAGE - Both surfaces of the lens are cleaned and disinfected, by a quick, uncomplicated process, giving prolonged use to the lens.
This is a prospective clinical validation study of a novel in-vitro diagnostic (IVD) assay that will enroll 830 pediatric patients. The study will be conducted in two stages: In stage A 50 patients will be enrolled with the aim of verifying proper protocol execution including proper collection of patient samples, accurate data retrieval and precise etiology determination. In stage B 780 patients will be enrolled with the aim of blinded validation of the host-response based diagnostics using a fresh independent cohort of patients. Patients enrolling into the study will be managed according to the current standard of care (GCP) and per standard institutional procedures. Participation in this study requires the collection of an additional blood sample and a nasal swab sampling.

The investigated assay requires the measurement of three host-related, blood-based, protein biomarkers that are being integrated using a logistic regression formula into a single score. Based on this score, each patient is classified into one of three categories: (i) bacterial immune response (i.e., pure bacterial infections and mixed bacterial and viral co-infection), (ii) viral immune response, and (iii) marginal immune response (inconclusive or non-infectious). It is estimated that 10-20% of the infected patients will have a marginal immune response. A composite reference standard will be used in order to determine the diagnosis of each patient. Specifically, all the clinical, radiological, microbiological and laboratory data of each patient, will be recorded in a dedicated eCRF. Based on this data, the diagnosis of each patient will be determined by a panel of three independent pediatricians. Each pediatrician will be blinded to the diagnosis of his peers and to the assay results. In the current study, unanimous agreement between the experts ("consensus agreement") will be considered as the true diagnosis for the purpose of computing the assay performance.
Cancer is second only to coronary artery disease, as being the most common cause of death. Progress in diagnosis and treatment 1ms had a significant effect on survival for some cancers, but the most common cancers such as lung and large bowel remain the most refractory. This study presents an effective cancer treatment via solar sonic electromagnetic chemical which is infusionably accessible and comprehensively coded for a variety of cancer conditions. All cancerous toxic components will undergo a form of physiological/ genetic/ reverse engineering. All potential pharmacological toxicity will be chemically reformulated and recondensed to specifically penetrate carcinogenic cells and lead to gradual eradication without affecting healthy cells, blood components or other internal organs. This invention relates to a medical device especially designed to treat cancer through a mechanism of promoting cytostasis, impairing mitosis, infusing cytochrome C-Protein and programming T-Lymphocyte/ T-Cells, as well as B-Lymphocyte/ B-Cells, thymus gland and inducing apoptosis; all done simultaneously with a medicament selected from highly proprietary pharmaceutically infused therapeutic composition and immunotherapeutic agents, immunomodulators, and- antigenic agents, angiogenesis inhibitors, vascular sealing agents, gene-therapy agents, antibiotic resistant modification agents and a photodynamic therapy agents. The said medical device with all of its accompanying therapeutic infusion composition and other varied supporting capabilities can be used in oncology for the treatment of primary and metastatic tumors.
Adolescents with chronic medical conditions are at increased risk for anxiety and depression compared to other people their age. Therapies that use role-play prevent anxiety and depression. However, often these studies do not have an underlying psychological framework, or there is not enough information to replicate the program. Investigators designed an intervention using role-play based on Integrative Community Therapy, developed in the 1980s by Dr. Adalberto Barreto. This program will help adolescents with chronic medical conditions explore their feelings about issues related to having a chronic condition, learn new coping strategies, and help one another find support among peers.

This treatment will take place once a week for 10 weeks and investigators will compare the effects to those derived from improvisational theatre alone. To evaluate this new treatment, the study team will screen participants for anxiety, depression, quality of life, and will give a short qualitative interview. This will occur before and after the intervention, 6 months after the intervention, and 1 year after the intervention.
This is an observational study evaluating changes in lung volume during hypoxemia episodes (HEs or desaturation episodes) in spontaneously breathing very preterm infants. We postulate that HEs can be differentiated into distinct subtypes based on alterations in lung volume. Additionally, the severity and duration of HEs correlates with the degree of changes in lung volumes. Therefore, we are performing an observational study in very preterm infants with spontaneous HEs and classifying these episodes into different subtypes of Apnea, forced exhalation, mixed, and unclassified subtypes according to changes in lung volume. Lung volume will be measured non-invasively using electrical impedance tomography (EIT) device (Sentec Inc, RI, USA). In brief, the device consists of a soft belt with 32 embedded electrodes which is placed around the chest of the infant and applies a weak alternating current and measures returning voltage. The measured returning voltage is dependent on the electrical conductivity of the underlying tissue. The reconstruction algorithm creates an image of regional impedance distribution in real time. These data are then used to compute lung volume parameters at different phases of respiratory cycle providing end expiratory lung impedance reflective of EELV, tidal impedance reflective of tidal volume, and regional distribution of ventilation. The changes in lung volume parameters will be used to differentiate HEs into different subtypes and correlated with degree and severity of HEs. In addition, we will also measure cerebral tissue oxygen saturation (CrSO2) to monitor changes in tissue oxygenation with hypoxemia episodes and changes in lung volume.
SEPTIC is a master protocol for two trials on distinct subpopulations: emergency department (ED) patients and inpatients. This protocol "ID: AAAU1002 - IP" describes the inpatient subpopulation study while "ID: AAAU1002 - ED" describes the ED subpopulation study.

Sepsis is a major cause of death both globally and in the United States. Early identification and treatment of sepsis are crucial for improving outcomes. International guidelines recommend hospital sepsis screening programs, which are commonly implemented in the electronic health record (EHR) as an interruptive screening alert based on systemic inflammatory response syndrome (SIRS) criteria. Despite widespread use, it is unknown whether these sepsis screening and alert tools improve the delivery of high-quality sepsis care. This study tests interruptive (pop-up) EHR alerts. Epic Systems, the company that produces the EHR, refers to these types of alerts as BestPractice Advisories (BPAs).
One aspect is a method of improving sleep quality and/or subsequent behavioral outcome. Another aspect is a method of treating, preventing and/or reducing at least one of the risk, incidence or severity of at least one condition for which improved sleep quality is beneficial. These methods comprise orally administering the composition to the individual at a predetermined time prior to and/or concurrent with the ingestion of the meal. The combined blood glucose load of the composition and the meal is lower than the blood glucose load of the meal and is from about 0.0 to about 45.0. Preferably, the meal is an equilibrated dinner and the composition is a food, supplement or liquid beverage, such as a ready-to-drink beverage or a beverage reconstituted from a powder. The composition may contain one or more of tryptophan, a glucosidase inhibitor, an arginine-proline (AP) dipeptide, fiber, resistant starch, beta-glucan, a-cyclodextrin, glucosidase, polyphenol, or an amylase inhibitor.
Up to 18 participants will be consented for this Parent Management Training (PMT) to Treat Irritability study in order to meet the aim of having 12 participants complete the study. The child participant and a parent will complete a pre-treatment study visit to evaluate mental health, behavior and cognitive functioning. Participants who meet inclusion criteria (age 10-14 with significant irritability) and do not meet exclusion criteria (e.g. Autism, Bipolar disorder, active PTSD, serious medical issues or Intellectual disability) will be invited to join the trial. All participants will receive an active treatment of 12 PMT sessions from a licensed or license eligible clinician supervised by a licensed clinician. These session will focus on the parents only, but both the parent and child will complete standardized measures during treatment. After the 12 sessions of PMT, the parent and child will complete a post-treatment visit to complete measures. Pre and post treatment measures will be compared to determine improvement in irritability as well as other areas of functioning.
A contact lens product includes a multifocal contact lens and a buffer solution, wherein the contact lens is immersed in the buffer solution. The multifocal contact lens includes a central region and at least one annular region. The annular region surrounds the central region. A diopter of the annular region is different from a diopter of the central region. The annular region closest to a periphery of the multifocal contact lens is a first annular region. When the specific condition is satisfied, the myopia can be prevented, or the progression of the myopia can be controlled.